secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aktis Oncology, Inc. (AKTS)
CIK:        0002035832
Form:       8-K
Filed at:   2026-05-11T20:04:15+00:00
Accession:  0001193125-26-216716
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing
-------------------------------------------------------------------------------

- Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.
- Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.
- Initiated Phase 1b trial of AKY-2519 in mCRPC; second basket trial in H2 2026 for solid tumors.
- AKY-1189 Phase 1b enrolling in multiple Nectin-4 tumors; preliminary data expected Q1 2027; FDA Fast Track for urothelial cancer.
- Collaboration revenue $3.2M from Eli Lilly; appointed Glenn Gormley, MD, PhD to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/0001193125-26-216716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/ck0002035832-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer